Laparoscopy

Laparoscopic Instruments Market worth $22.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

Friday, April 16, 2021 - 2:30pm

Surgeons and patients visiting hospitals for various treatments are at increased risk of contracting COVID-19.

Key Points: 
  • Surgeons and patients visiting hospitals for various treatments are at increased risk of contracting COVID-19.
  • This has severely impacted healthcare revenue, as elective surgeries account for ~20% of the total healthcare revenue in countries such as the US.
  • This had a negative impact on the surgical devices market, including the laparoscopic instruments market, in 2020.\nBased on product, the global market is segmented into medical laparoscopic robots, energy devices, insufflators, suction/irrigation systems, laparoscopes, hand instruments, closure devices, access devices, and accessories.
  • Medical laparoscopic robots holds maximum share of the global laparoscopic instruments market in 2020.

Laparoscopic Instruments Market worth $22.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

Friday, April 16, 2021 - 2:30pm

Surgeons and patients visiting hospitals for various treatments are at increased risk of contracting COVID-19.

Key Points: 
  • Surgeons and patients visiting hospitals for various treatments are at increased risk of contracting COVID-19.
  • This has severely impacted healthcare revenue, as elective surgeries account for ~20% of the total healthcare revenue in countries such as the US.
  • This had a negative impact on the surgical devices market, including the laparoscopic instruments market, in 2020.\nBased on product, the global market is segmented into medical laparoscopic robots, energy devices, insufflators, suction/irrigation systems, laparoscopes, hand instruments, closure devices, access devices, and accessories.
  • Medical laparoscopic robots holds maximum share of the global laparoscopic instruments market in 2020.

Olympus Opens New Global HQ for Therapeutic Solutions Division and U.S. Medical Business

Thursday, April 8, 2021 - 2:00am

Olympus opens global headquarters for Therapeutic Solutions and Medical Business in Westborough, MA, U.S.

Key Points: 
  • Olympus opens global headquarters for Therapeutic Solutions and Medical Business in Westborough, MA, U.S.
  • Since the Transform Olympus initiatives were unveiled in 2019, many U.S.-based executives have been leading TSD growth; Olympus has dramatically expanded the business with acquisitions, as well as through organic growth.
  • The facility will serve as one of several R&D hubs for Olympus, while enabling coordinated and agile management processes to support a global medical technology enterprise.
  • Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications.

Wyntrea L. Cunningham MD is recognized by Continental Who's Who

Tuesday, April 6, 2021 - 6:41pm

HOUSTON, April 6, 2021 /PRNewswire/ --Wyntrea L. Cunningham MD is being recognized by Continental Who's Who as a Top Obstetrics & Gynecology Specialist for her remarkable contributions in the medical field and her professional excellence at THC MediSpa and Clinic.

Key Points: 
  • HOUSTON, April 6, 2021 /PRNewswire/ --Wyntrea L. Cunningham MD is being recognized by Continental Who's Who as a Top Obstetrics & Gynecology Specialist for her remarkable contributions in the medical field and her professional excellence at THC MediSpa and Clinic.
  • At THC MediSpa & Clinic, primary provider Dr. Wyntrea L. Cunningham and her staff strive to deliver unparalleled service and solutions designed to meet each patient's unique needs.
  • In her current capacity, Dr. Cunningham performs invasive and minimally invasive surgery, including laparoscopic surgery.
  • Furthering her medical training, Dr. Cunningham completed her Obstetrics and Gynecology residency at the UT Houston McGovern Medical School.

Erbe Elektromedizin to acquire Maxer Endoscopy

Tuesday, April 6, 2021 - 12:00pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210406005418/en/
    From left to right: Christian O. Erbe, CEO Erbe Elektromedizin GmbH, Shirish Joshi, General Manager Maxer Endoscopy GmbH, Gayatri Joshi, Shareholder Maxer Endoscopy GmbH, Daniel Zimmermann, CFO Erbe Elektromedizin GmbH, and Marcus Felstead, CMO Erbe Elektromedizin GmbH.
  • Entering into the world of fluorescence imaging systems is the logical first step to provide the required added value to our customers", according to Christian O. Erbe, CEO & President at Erbe Elektromedizin GmbH.
  • Now, Erbe will be able to offer best-in-class performance with 4K and fluorescence-guided systems in endoscopy as well as for open surgeries.
  • Maxer manufactures a wide range of endoscopic systems and instruments for laparoscopy, hysteroscopy, urology, pediatric surgery, arthroscopy, spine endoscopy and ENT surgery.

Asensus Surgical Announces Finalization of Name and Ticker Symbol Change

Friday, March 5, 2021 - 11:55am

Asensus Surgical , Inc. (formerly TransEnterix, Inc.) (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, today announced the formal completion of its previously announced name and ticker symbol change.

Key Points: 
  • Asensus Surgical , Inc. (formerly TransEnterix, Inc.) (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, today announced the formal completion of its previously announced name and ticker symbol change.
  • Effective today, Friday March 5, 2021, the Companys stock will trade on the NYSE American under its new ticker symbol ASXC, and name, Asensus Surgical, Inc.
  • The previous ticker symbol was TRXC, and the previous name was TransEnterix, Inc.
    No actions are needed from current stockholders relative to the ticker symbol change.
  • This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability.

Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Conference Call for March 11, 2021

Thursday, March 4, 2021 - 11:55am

The Company will host a conference call to discuss these results starting at 4:30 p.m.

Key Points: 
  • The Company will host a conference call to discuss these results starting at 4:30 p.m.
  • To listen to the conference call on your telephone, please dial 1-855-327-6837 for domestic callers and 1-631-891-4304 for international callers, and reference conference ID 10013234 approximately ten minutes prior to the start time.
  • To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations .
  • Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com .

Asensus Surgical Announces FDA Clearance in General Surgery

Wednesday, March 3, 2021 - 11:55am

The expansion into general surgery for the Senhance Surgical System is a major milestone for the growth and clinical applicability of our technology, said Anthony Fernando, Asensus Surgical President and CEO.

Key Points: 
  • The expansion into general surgery for the Senhance Surgical System is a major milestone for the growth and clinical applicability of our technology, said Anthony Fernando, Asensus Surgical President and CEO.
  • General surgery is, by far, the largest area of manual laparoscopy which can benefit from the precision and insight of Performance-Guided Surgery.
  • The Senhance Surgical System is intended for use in general laparoscopic surgical procedures and laparoscopic gynecological surgery.
  • This press release includes statements relating to the Senhance Surgical System and the FDA clearance to allow for a US indication in general surgery.

Asensus Surgical to Present at the H.C. Wainwright Virtual Global Life Sciences Conference

Monday, March 1, 2021 - 11:55am

The Companys presentation will be available for on-demand beginning Tuesday, March 9, 2021 at 7:00 am ET.

Key Points: 
  • The Companys presentation will be available for on-demand beginning Tuesday, March 9, 2021 at 7:00 am ET.
  • The on-demand conference presentation will be available online on the investor relations page of the Companys website at https://ir.asensus.com/events-and-presentations .
  • This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability.
  • Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com .

TransEnterix Announces Name Change to Asensus Surgical and Introduces a New Category of Surgery, Performance-Guided Surgery

Tuesday, February 23, 2021 - 3:53pm

The name change reflects the company's broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics.

Key Points: 
  • The name change reflects the company's broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics.
  • Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.
  • Today, the Senhance Surgical System is being used by over 100 active surgeon users across three continents with over 4,000 procedures performed across a wide variety of surgical specialties.
  • As part of the name change, Asensus Surgical also released a new company logo and rebranded the company website at www.Asensus.com .